Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology

All authors contributed to the conception and design of this study. Material preparation, data collection, and analysis were performed by TH, SY, and YM. The first draft of the manuscript was written by TH, and all authors commented on previous versions of the manuscript. All the authors have read and approved the final manuscript.

Comments (0)

No login
gif